The ABCs of RVO: A review of retinal venous occlusion

Clinical and Experimental Optometry

Volumn 97, Issue 4, 2014, Pages 311-323

  Macdonald, Derek ^a  

^a NONE   (Canada)

Author keywords

Aflibercept; Bevacizumab; Macular oedema; Pegaptanib; Ranibizumab; Retinal vein occlusion; Sheathotomy; Vascular endothelial growth factor; Vitrectomy

Indexed keywords

FIBRINOLYTIC THERAPY; HEMODILUTION; HUMAN; LASER COAGULATION; PROCEDURES; RETINAL VEIN OCCLUSION; VISUAL ACUITY; VITRECTOMY;

HEMODILUTION; HUMANS; LASER COAGULATION; RETINAL VEIN OCCLUSION; THROMBOLYTIC THERAPY; VISUAL ACUITY; VITRECTOMY;

EID: 84920429078     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/cxo.12120     Document Type: Review

References (183)

1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Tr Am Ophthalmol Soc 2000; 98: 133-143.
2. Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 2010; 4: 809-816.
3. Wong TY, Scott IU. Retinal-vein occlusion. N Engl J Med 2010; 363: 2135-2144.
4. The Eye Disease Case Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545-554.
5. Klein R, Klein BE, Lee KE, Cruickshanks KJ, Gangnon RE. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol 2006; 142: 539-549.
6. McAllister IL. Central retinal vein occlusion: a review. Clin Experiment Ophthalmol 2012; 40: 48-58.
7. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008; 33: 111-131.
8. Hayreh SS, Zimmerman MB. Hemicentral retinal vein occlusion. Natural history and visual outcome. Retina 2012; 32: 68-76.
9. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 2011; 56: 281-299.
10. Williamson TH. Central retinal vein occlusion: what's the story? Br J Ophthalmol 1997; 81: 698-704.
11. Rehak M, Wioedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010; 8: 1886-1894.
12. Hayreh SS, Zimmerman BH. Amaurosis fugax in ocular vascular occlusive disorders. Retina 2013; April 29 [Epub ahead of print].
13. Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol 2012; 23: 175-181.
14. Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion. Epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 2013; 33: 901-910.
15. Jonas JB. Ophthalmodynamometric assessment of the central retinal vein collapse pressure in eyes with retinal vein stasis or occlusion. Graefes Arch Clin Exp Ophthalmol 2003; 241: 367-370.
16. Noma H, Mimura T, Eguchi S. Association of inflammatory factors with macular oedema in branch retinal vein occlusion. JAMA Ophthalmol 2013; 131: 160-165.
17. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology 2013; 120: 106-114.
18. Laatikainen L, Kohner EM. Fluorescein angiography and its prognostic significance in central retinal vein occlusion. Br J Ophthalmol 1976; 60: 411-418.
19. Noma H, Funatsu H, Mimura T, Shimada K. Visual function and serous retinal detachment in patients with branch retinal vein occlusion and macular oedema: a case series. BMC Ophthalmol 2011; 11: 29-35.
20. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 2011; 118: 119-133.
21. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 2013; 120: 795-802.
22. Zhou JQ, Xu L, Wang S, Wang YX, You QS, Tu Y, Yang H etal. The 10-year incidence and risk factors of retinal vein occlusion. Ophthalmology 2013; 120: 803-808.
23. Duker JS, Brown GC. Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophthalmol 1989; 107: 998-1000.
24. Waisbren EC, Salz DA, Brown MM, Brown GC. Vascular crossing patterns in patients with systemic arterial hypertension. Br J Ophthalmol 2013; 97: 781-784.
25. Hayreh SS, Zimmerman MB. Fundus changes in central retinal artery occlusion. Retina 2007; 27: 276-289.
26. Goldberg N, Freund KB. Progressive optic nerve collateralization after serial intravitreal ranibizumab injections for central retinal vein occlusion. Retina 2013; 33: 449-450.
27. Saeed MU, Gkaragkani E, Eli K. Emerging roles for antiangiogenesis factors in management of ocular disease. Clin Ophthalmol 2013; 7: 533-543.
28. Chan CK, Ip MS, VanVeldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA etal. SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology 2011; 118: 1364-1372.
29. Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol 2006; 90: 627-639.
30. The Central Retinal Vein Occlusion Study Group. A randomized clinical trial of early panretinal photogoagulation for ischaemic central vein occlusion. Ophthalmology 1995; 102: 1434-1444.
31. Sakamoto A, Tusjikawa A, Ota M, Yamaike N, Kotera Y, Miyamoto K, Kita M etal. Evaluation of potential acuity in eyes with macular oedema secondary to retinal vein occlusion. Clin Experiment Ophthalmol 2009; 37: 208-216.
32. Kang HM, Chung EJ, Kim YM, Koh HJ. Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular oedema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2013; 251: 501-508.
33. Ota M, Tsujikawa A, Murakami T, Kita M, Miyamoto K, Sakamoto A, Yamsike N etal. Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 2007; 91: 1644-1649.
34. Sekiryu T, Iida T, Sakai E, Maruko I, Ojima A, Sugano Y. Fundus autofluorescence and optical coherence tomography findings in branch retinal vein occlusion. J Ophthalmol 2012; 2012: 638064.
35. Recchia FM, Carvalho-Recchia CA, Hassan TS. Clinical course of younger patients with central retinal vein occlusion. Arch Ophthalmol 2004; 122: 317-321.
36. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Hartnett ME, Cohen G etal. Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: standard care versus corticosteroid for retinal vein occlusion study report 10. Ophthalmology 2011; 118: 345-352.
37. Manayath GJ. Bevacizumab (Avastin) therapy for macular oedema in central retinal vein occusion-long term results. Kerala J Ophthalmol 2008; 20: 355-361.
38. Mirashi A, Roohipoor R, Lashay A, Mohammadi SF, Mansouri MR. Surgical induction of chorioretinal venous anastomosis in ischaemic central retinal vein occlusion: a non-randomised controlled clinical trial. Br J Ophthalmol 2005; 89: 64-69.
39. Shah NJ, Shah UN. Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular oedema: a pilot study. Eye 2011; 25: 239-244.
40. Decroos FL, Fekrat S. The natural history of retinal vein occlusion: what do we really know? Am J Ophthalmol 2011; 151: 739-741.
41. Channa R, Smith M, Campochiaro PA. Treatment of macular oedema due to retinal vein occlusions. Clin Ophthalmol 2011; 5: 705-713.
42. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC etal. Ranibizumab for macular oedema following central retinal vein occlusion. Ophthalmology 2010; 117: 1124-1133.
43. Keane PA, Sadda SR. Retinal vein occlusion and macular oedema-critical evaluation of the clinical value of ranibizumab. Clin Ophthalmol 2011; 5: 771-781.
44. Prager F, Michels S, Kreichbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, etal. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009; 63: 452-456.
45. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 2012; 87: 77-88.
46. Alasil T, Lee N, Keane P, Sadda S. Central retinal vein occlusion: a case report and review of the literature. Cases J 2009; 2: 7170-7173.
47. Lattanzio R, Torres Gimeno A, Battaglia Parodi M, Bandello F. Retinal vein occlusion: current treatment. Ophthalmologica 2011; 225: 135-143.
48. Bertelsen M, Linneberg A, Rosenberg T, Christoffersen N, Vorum H, Gade E, Larsen M. Comorbidity in patients with branch retinal vein occlusion: case-control study. BMJ 2013; 345: e7885.
49. Appiah AP, Trempe CL. Risk factors associated with branch vs. central retinal vein occlusion. Ann Ophthalmol 1989; 21: 153-157.
50. Alexander LJ. Primary Care of the Posterior Segment. East Norwalk, Connecticut: Appleton & Lange, 1989. p 117-128.
51. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activate protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996; 80: 203-208.
52. Elman MJ. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Tr Am Ophthalmol Soc 1996; 94: 471-504.
53. Stem MS, Talwar N, Comer GM, Stein JD. A longitudinal analysis of risk factors associated with central retinal vein occlusion. Ophthalmology 2013; 120: 362-370.
54. Kohner EM, Pettit JE, Hamilton AM, Bulpitt CJ, Dollery CT. Streptokinase in central retinal vein occlusion: a controlled clinical trial. BMJ 1976; 1: 550-553.
55. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996; 80: 200-202.
56. Koizumi H, Ferrara DC, Brue C, Spaide RF. Central retinal vein occlusion case-control study. Am J Ophthalmol 2007; 144: 858-863.
57. Johnson TM, El-Defrawy S, Hodge WG, Leonard BC, Kertes PJ, Taylor SAM, Lillicrap DP. Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion. Retina 2001; 21: 161-166.
58. Chou KT, Huang CC, Tsai DC, Chen YM, Perng DW, Shiao GM, Lee YC etal. Sleep apnea and risk of retinal vein occlusion: a nationwide population-based study of Taiwanese. Am J Ophthalmol 2012; 154: 200-205.
59. Maier R, Steinbrugger I, Haas A, Selimovic M, Renner W, El-Shabrawi Y, Werner C etal. Role of inflammation-related gene polymorphisms in patients with central retinal vein occlusion. Ophthalmology 2011; 118: 1125-1129.
60. Steinbrugger I, Haas A, Maier R, Renner W, Mayer M, Werner C, Wedrich A etal. Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion. Mol Vis 2009; 15: 609-618.
61. Ortak H, Demir S, Ates O, Sogut E, Alim S, Benli I. Association of MMP2-1306C/T and TIMP2G-418C polymorphisms in retinal vein occlusion. Exp Eye Res 2013; 113: 151-155.
62. Mahmood T. Central retinal vein occlusion: current management options. Pak J Ophthalmol 2009; 25: 1-4.
63. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-491.
64. th World Glaucoma Congress; 2013 July 17-20; Vancouver, BC, Canada.
65. Sin BH, Song BJ, Park SP. Aqueous vascular endothelial growth factor and endothelin-1 levels in branch retinal vein occlusion associated with normal tension glaucoma. J Glaucoma 2013; 22: 104-109.
66. Kress WD. Retinal venous occlusions: a systematic review and update on current treatment options. Rev Optom 2010; 11: 12-17.
67. La Spina C, De Benedetto U, Battaglia Parodi M, Coscas G, Bandello F. Practical management of retinal vein occlusions. Ophthalmol Ther 2012; 1: 1-10.
68. Khan Z, Almeida DR, Rahim K, Belliveau MJ, Bona M, Gale J. 10-year Framingham risk in patients with retinal vein occlusion: a systematic review and meta-analysis. Can J Ophthalmol 2013; 48: 40-45.
69. Hansen LL, Wiek J, Wiederholt M. A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 1989; 73: 895-899.
70. Glacet-Bernard A, Atassi M, Fardeau C, Romanet JP, Tonini M, Conrath J, Denis P etal. Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study. Graefes Arch Clin Exp Ophthalmol 2011; 249: 505-512.
71. Hayreh SS, Podhajsky PA, Zimmerman MB. Central and hemicentral retinal vein occlusion. Role of anti-platelet aggregation agents and anticoagulants. Ophthalmology 2011; 118: 1603-1611.
72. Maeda K, Ishikawa F, Ohguro H. Ocular blood flow levels and visual prognosis in a patient with nonischaemic type central retinal vein occlusion. Clin Ophthalmol 2009; 3: 489-491.
73. Pournaras CJ, Petropoulos IK, Pournaras JA, Stangos AN, Gilodi N, Rungger-Brandle E. The rationale of retinal endovascular fibrinolysis in the treatment of retinal vein occlusion. Retina 2012; 32: 1566-1573.
74. Bynoe LA, Hutchins RK, Lazarus HS, Friedberg MA. Retinal endovascular surgery for central retinal vein occlusion: initial experience of four surgeons. Retina 2005; 25: 625-632.
75. Madhusudhana KC, Newsom RSB. Central retinal vein occlusion: the therapeutic options. Can J Ophthalmol 2007; 42: 193-195.
76. McAllister IL, Gillies ME, Smithies LA, Rochtchina E, Harper CA, Daniell MD, Constable IJ etal. The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion. Ophthalmology 2010; 117: 954-965.
77. Fekrat S, Goldberg MF, Finkelstein D. Laser-induced chorioretinal venous anastomosis for nonischaemic central or branch retinal vein occlusion. Arch Ophthalmol 1998; 116: 43-52.
78. Chen CH, Laii CH, Kuo HK. Laser chorioretinal venous anastomosis for progressive non-ischaemic central retinal vein occlusion. Chang Gung Med J 2005; 28: 866-871.
79. McAllister IL, Gillies ME, Smithies LA, Rochtchina E, Harper CA, Daniell MD, Constable IJ etal. Factors promoting success and influencing complications in laser-induced central vein bypass. Ophthalmology 2012; 119: 2579-2586.
80. Opremcak ME, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina 1999; 19: 1-5.
81. Figueroa MS, Torres R, Alvarez MT. Comparative study of vitrectomy with and without vein decompression for branch retinal vein occlusion: a pilot study. Eur J Ophthalmol 2004; 14: 40-47.
82. Leizaola-Fernandez C, Suarez-Tata L, Quiroz-Mercado H, Colina-Luquez J, Fromow-Guerra J, Jimenez-Sierra JM, Guerrero-Naranjo JL etal. Vitrectomy with complete posterior hyaloid removal for ischaemic central retinal vein occlusion: series of cases. BMC Ophthalmol 2005; 5: 10-14.
83. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion. An evidence-based systematic review. Ophthalmology 2007; 114: 507-519.
84. Stefansson E, Novack RL, Hatchell DL. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 1990; 31: 284-289.
85. Jackson TL, Nicod E, Angelis A, Grimaccia F, Prevost AT, Simpson AR, Kanavos P. Vitreous attachment in age-related macular degeneration, diabetic macular oedema, and retinal vein occlusion. Retina 2013; 33: 1099-1108.
86. Okunuki Y, Usui Y, Katai N, Kezuka T, Takeuchi M, Goto H, Wakabayashi Y. Relation of intraocular concentrations of inflammatory factors and improvement of macular oedema after vitrectomy in branch retinal vein occlusion. Am J Ophthalmol 2011; 141: 610-616.
87. Noma H, Mimura T, Masahara H, Shimada K. Pentraxin 3 and other inflammatory factors in central retinal vein occlusion and macular oedema. Retina 2013; July 9.[Epub ahead of print]..
88. Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ. Radial optic neurotomy for central retinal vein occlusion. Retina 2001; 41: 408-415.
89. Weizer JS, Stinnett SS, Fekrat S. Radial optic neurotomy as treatment for central retinal vein occlusion. Am J Ophthalmol 2003; 136: 814-819.
90. Hayreh SS, Zimmerman MB, Podhajsky PA. Retinal vein occlusion and the optic disk. Retina 2012; 32: 2108-2118.
91. Tao Y, Jiang YP, Li XX, Yin CY, Yao J. Fundus and histopathological study of radial optic neurotomy in the normal miniature pig eye. Arch Ophthalmol 2005; 123: 1097-1101.
92. Garcia-Arumii J, Boixadera A, Martinez-Castillo V, Castillo R, Dou A, Corcostegui B. Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol 2003; 121: 1385-1391.
93. Maia M, Farah ME, Aggio FB, Rodrigues EB, de Souza EC, Magalhaes O Jr. Peripapillary haemorrhagic retinal pigment epithelium detachment following radial optic neurotomy. Clin Experiment Ophthalmol 2007; 35: 672-674.
94. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular oedema in branch vein occlusion. Am J Ophthalmol 1984; 98: 271-282.
95. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion. An evidence-based systematic review. Ophthalmology 2007; 114: 835-846.
96. Udaondo P, Garcia-Delpech S, Salom D, Garcia-Pous M, Diaz-Llopis M. Intravitreal pegaptanib for refractory macular oedema secondary to retinal vein occlusion. Clin Ophthalmol 2011; 5: 941-944.
97. Arnarsson A, Stefansson E. Laser treatment and the mechanism of oedema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 2000; 41: 877-879.
98. May DR, Klein ML, Peyman GA, Raichand M. Xenon arc panretinal photocoagulation for central retinal vein occlusion: a randomised prospective study. Br J Ophthalmol 1979; 63: 725-734.
99. The Central Retinal Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular oedema in central vein occlusion. Ophthalmology 1995; 102: 1425-1433.
100. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular oedema secondary to central retinal vein occlusion. Arch Ophthalmol 2009; 127: 1101-1114.
101. Laatikainen L, Kohner EM, Khoury D, Blach RK. Panretinal photocoagulation in central retinal vein occlusion: a randomised controlled clinical study. Br J Ophthalmol 1977; 61: 741-753.
102. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
103. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin N Am 2006; 19: 335-344.
104. Smit DP, Meyer D. Intravitreal bevacizumab: an analysis of the evidence. Clin Ophthalmol 2007; 1: 273-284.
105. 165b are increased in vitreous of patients with retinal vein occlusion. Am J Ophthalmol 2011; 152: 298-303.
106. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS etal. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion. Retina 2007; 27: 1004-1012.
107. Deissler HL, Deissler H, Lang GE. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences. Br J Ophthalmol 2012; 96: 1023-1028.
108. Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer DR etal. Pegabtanib sodium for macular oedema secondary to central retinal vein occlusion. Arch Ophthalmol 2009; 127: 374-380.
109. Moisseiev E, Goldstein M, Waisbourd M, Barak A, Lowenstein A. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular oedema due to retinal vein occlusion. Eye 2013; 27: 65-71.
110. Sharma A, Kupperman BD, Kenney MC. Use of intravitreal triamcinolone in the treatment of macular oedema related to retinal vein occlusion. Open Ophthalmol J 2008; 2: 68-72.
111. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular oedema secondary to branch retinal vein occlusion. Arch Ophthalmol 2009; 127: 1115-1128.
112. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Domalpally A, Doft BH, Elman MJ etal. Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study. Arch Ophthalmol 2012; 130: 1517-1524.
113. Apte RS. SCOREing in retinal venous occlusive disease. Arch Ophthalmol 2009; 127: 1203-1204.
114. Noma H, Mimura T. Macular sensitivity and morphology after intravitreal injection of triamcinolone acetonide for macular oedema secondary to central retinal vein occlusion. Clin Ophthalmol 2012; 6: 1901-1906.
115. Collet L, Larson TA, Bakri SJ. Bevacizumab for ophthalmic disease. US Ophthalmic Rev 2007; 2: 20-24.
116. Singer MA, Bell DJ, Woods P, Pollard J, Boord T, Herro A, Porbandarwalla S. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina 2012; 32: 1289-1294.
117. Lim JI, Fung AE, Wieland M, Hung D, Wong V. Sustained-release intravitreal liquid drug delivery using triamcinolone acetonide for cystoid macular oedema in retinal vein occlusion. Ophthalmology 2011; 118: 1416-1422.
118. Chan A, Leung LS, Blumenkranz MS. Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular oedema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol 2011; 5: 1043-1049.
119. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A etal. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular oedema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.
120. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A etal. Dexamethasone intravitreal implant in patients with macular oedema related to branch or central retinal vein occlusion. Ophthalmology 2011; 118: 2453-2460.
121. Capone A, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG etal. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular oedema related to retinal vein occlusion (SHASTA Study). Retina 2013; July 10. [Epub ahead of print].
122. Yeh WS, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, Whitcup SM etal. Effect of the duration of macular oedema on clinical outcome in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 2012; 119: 1190-1198.
123. Sadda S, Danis RP, Pappuru RR, Keane PA, Jiao J, Li XY, Whitcup SM. Vascular changes in eyes treated with dexamethasone intravitreal implant for macular oedema after retinal vein occlusion. Ophthalmology 2013; 120: 1423-1431.
124. Pearson PA, Comstock TL, Ip M, Callanan D, Morse LS, Ashton P, Levy B etal. Fluocinolone acetonide intravitreal implant for diabetic macular oedema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118: 1580-1587.
125. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature 2006; 5: 123-132.
126. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 2012; 154: 222-226.
127. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M. Targeted deletion of VEGFA in adult mice induces vision loss. J Clin Invest 2012; 122: 4213-4217.
128. Benny O, Nakai K, Yoshimura T, Bazinet L, Akula JD, Nakao S, Hafezi-Moghadam A etal. Broad spectrum antiangiogenic treatment for ocular neovascular diseases. PLoS ONE 2010; 5: 1-14.
129. Marticorena J, Romano MR, Heimann H, Stappler T, Gibran K, Groenewald C, Pearce I etal. Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect? Br J Ophthalmol 2011; 95: 391-395.
130. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335.
131. Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn't blind people, people blind people. Am J Ophthalmol 2012; 153: 196-203.
132. Smiddy WE. Economic considerations of macular oedema therapies. Ophthalmology 2011; 118: 1827-1833.
133. Al-Qureshi S, Shaikh S. Intravitreous bevacizumab adult safety data: the evidence so far. Clin Exp Ophthalmol 2012; 40: 3-5.
134. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Bevacizumab for macular oedema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 2012; 119: 1184-1189.
135. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB etal. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular oedema in retinal vein occlusion. Am J Ophthalmol 2007; 143: 601-606.
136. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions. Retina 2007; 27: 141-149.
137. Abegg M, Tappeiner C, Wolf-Schnurrbusch U, Barthelmes D, Wolf S, Fleischhauer J. Treatment of branch retinal vein occlusion induced macular oedema with bevacizumab. BMC Ophthalmol 2008; 8: 18.
138. Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 2008; 19: 234-238.
139. Yalamanchi Y, Flynn HW. Hemicentral vein occlusion with macular hemorrhage and oedema treated with intravitreal bevacizumab. Clin Ophthalmol 2011; 5: 1509-1513.
140. ul-Hussan M, Qidwai U, ur-Rehman A, Sial N, Bhatti N. Visual outcome after intravitreal bevacizumab injection in macular oedema secondary to central retinal vein occlusion. Pak J Ophthalmol 2011; 27: 84-88.
141. Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Canton V, Alezzandrini AA etal. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular oedema secondary to central retinal vein occlusion. Retina 2010; 30: 1002-1011.
142. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular oedema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012; 119; 2587-2591.
143. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 2007; 35: 494-496.
144. Gillies MC. Bevacizumab in ophthalmology: the controversy moves forward. Clin Experiment Ophthalmol 2010; 38: 333-334.
145. Gutierrez JCM, Barquet LA, Caminal JM, Mitjana O, Almolda SP, Domenech NP, Goita OP, etal. Intravitreal bevacizumab (Avastin) in the treatment of macular oedema secondary to retinal vein occlusion. Clin Ophthalmol 2008; 2: 787-791.
146. Gallego-Pinazo R, Dolz-Marco R, Diaz-Llopis M. Ranibizumab is not bevacizumab for retinal vein occlusions. Graefes Arch Clin Exp Ophthalmol 2012; 250: 955-956.
147. Brown DM. Clinical implications of the BRAVO and CRUISE trials. Retina Today 2010; 4: 38-40.
148. CRUISE Research Group. A study of the efficacy and safety of ranibizumab injection in subjects with macular oedema secondary to central retinal vein occlusion. ClinicalTrials.gov-http://clinicaltrials.gov/ct2/show/NCT00485836
149. Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology 2013; 120: 1057-1063.
150. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY etal. Sustained benefits from ranibizumab for macular oedema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049.
151. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P. Ranibizumab for macular oedema due to retinal vein occlusions. Long-term follow-up in the HORIZON Trial. Ophthalmology 2012; 119: 802-809.
152. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, etal. Sustained benefits from ranibizumab for macular oedema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594-1602.
153. Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG. Collaborative Anti-VEGF Ocular Vascular Complications Group. Insight into 144 patients with ocular vascular events during VEGF antagonist injections. Clin Ophthalmol 2012; 6: 343-363.
154. Jorge R, Oliveira RS, Messias A, Almeida FP, Strambe ML, Costa RA, Scott IU. Ranibizumab for retinal neovascularisation. Ophthalmology 2011; 118: 1004-1005.
155. Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 2012; 32: 1295-1301.
156. Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012; 119: 321-326.
157. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injection of anti-VEGF agents. Br J Ophthalmol 2011; 95: 1111-1114.
158. Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R etal. The DA VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular oedema. Ophthalmology 2011; 118: 1819-1826.
159. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G etal. Vascular endothelial growth factor trap-eye for macular oedema secondary to central retinal vein occlusion. Ophthalmology 2012; 119: 1024-1032.
160. Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, Stahl N etal. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 2011; 118: 1089-1097.
161. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, Strahl N etal. The 1-year results of CLEAR-IT2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011; 118: 1098-1106.
162. Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzback G, Vitti R etal. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 2013; 97: 278-284.
163. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, etal. Intravitreal aflibercept injection for macular oedema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS Study. Am J Ophthalmol 2013; 155: 429-437.
164. Hahn P, Fekrat S. Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place? Am J Ophthalmol 2013; 155: 415-417.
165. Kim JY, Park SP. Comparison between intravitreal bevacizumab and triamcinolone for macular oedema secondary to branch retinal vein occlusion. Korean J Ophthalmol 2009; 23: 259-265.
166. Ehlers JP, Fekrat S. Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion. Can J Ophthalmol 2011; 46: 88-89.
167. Mayer WJ, Wolf A, Kernt M, Kook D, Kampik A, Ulbig M, Haritoglou C. Twelve-month experience with Ozurdex for the treatment of macular oedema associated with retinal vein occlusion. Eye 2013; 27: 816-822.
168. Shah AM, Bressler NM, Jampol LM. Does laser still have a role in the management of retinal vascular and neovascular diseases? Am J Ophthalmol 2011; 152: 332-339.
169. Spaide RF. Prospective study of peripheral panretinal photocoagulation of areas of nonperfusion in central retinal vein occlusion. Retina 2013; 33: 56-62.
170. CATT Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2012; 119: 1388-1398.
171. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
172. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. Ophthalmology 2012; 119: 1399-1411.
173. Singer MA, Cohen SR, Groth SL, Porbandarwalla S. Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusion. Clin Ophthalmol 2013; 7: 1377-1383.
174. Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore 2008; 37: 591-593.
175. Lim LS, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned? Am J Ophthalmol 2011; 152: 329-331.
176. Ueta T, Mori H, Kunimatsu A, Yamaguchi T, Tamaki Y, Yanagi Y. Stroke and anti-VEGF therapy. Ophthalmology 2011; 118: 2093-2095.
177. Campbell RJ, Bell CM, Campbell Ede L, Gill SS. Systemic effects of intravitreal vascular endothelial growth factor inhibitors. Curr Opin Ophthalmol 2013; 24: 197-204.
178. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparing ranibizumab with bevacizumab. Ophthalmology 2011; 118: 600-600.e2.
179. Beaumont P. Bevacizumab: not as good with more adverse reactions? Clin Experiment Ophthalmol 2011; 39: 588-590.
180. Kemp A, Preen DB, Morlet N, Clark A, McAllister IL, Briffa T, Sanfilippo FM etal. Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors. Retina 2013; 33: 920-927.
181. Farjo KM, Ma J. The potential of nanomedicine therapies to treat neovascular disease in the retina. J Angiogenes Res 2010; 2: 21.
182. Wang X, Abraham S, McKenzie JAG, Jeffs N, Swire M, Tripathi VB, Luhmann UFO etal. LRG1 promotes angiogenesis by modulating endothelial TGF-β signaling. Nature 2013; 499: 306-313.
183. Sun C, Li XX, He XJ, Tao Y. Neuroprotective effect of minocycline in a rat model of branch retinal vein occlusion. Exp Eye Res 2013; 113: 105-116.